When treating rheumatoid arthritis, establishing insurance coverage guidelines regarding transitions between Janus kinase (JAK) inhibitors is urgently needed, a local rheumatology expert said. Professor Lee Sang-heon of the Rheumatology Department at Konkuk University Hospital spoke on the latest tr
Yuhan Corp. has recently revealed the success of the MARIPOSA clinical trial for Leclaza, its third-generation EGFR tyrosine kinase inhibitor (TKI). This development has sparked interest in whether it will mark the first global introduction of a homegrown anticancer drug.Professor Cho Byoung-chul, h
Barcelona, Spain -- A Korean company received high interest from overseas buyers at the world's largest pharmaceutical and biotechnology fair, CPHI Worldwide 2023, held in Barcelona, Spain, from Tuesday to Thursday.Alteogen, which has recombinant hyaluronidase (ALT-B4) technology, is the company. It
BARCELONA, Spain -- Daewoong Pharmaceutical, which participated in the world's largest pharmaceutical and bio exhibition, CPHI Worldwide 2023, showed confidence in the export competitiveness of homegrown P-CAB medications.In the CPHI 2023, held in Barcelona, Spain, from Tuesday to Thursday, Daewoong
Innovative medical technologies, such as digital treatment devices and diagnostic aids using artificial intelligence, have been decided to receive insurance benefits.The Ministry of Health and Welfare deliberated and approved the “Plan for Medical Benefits for Digital Therapeutic Devices and AI Inno
ICURE, a Korean biopharmaceutical company, has signed an export agreement with ANDK, a U.K.-based pharmaceutical trading company, to supply local anesthetics Plaster and Cataplasma in the Middle East and North Africa (MENA) region, including Kuwait, the UAE, and Egypt.ICURE specializes in the develo
SGLT2 inhibitor Jardiance (empagliflozin) has become a triple-crown treatment option in Korea, adding chronic kidney disease to its existing list of indications of type 2 diabetes and chronic heart failure, following Forxiga (dapagliflozin).Last Thursday, the Ministry of Food and Drug Safety (MFDS)
BARCELONA, Spain -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- "With the completion of the 33,000-square meter Innovative Discovery Center (IDC) in Busan in the first half of next year, we will further accelerate the R&D of new drugs and new biotechnologies through open innovation."On
In a strategic pivot, Medytox has altered its primary botulinum toxin (BTX) product to enter the Chinese market.According to the company, it recently decided to withdraw its drug registration application for Meditoxin (export name: Neuronox) with China's National Medical Products Administration (NMP
NKMAX, a Korean natural killer (NK) cell-based immunotherapy company, announced on Wednesday that its U.S. subsidiary, NKGen Biotech, has received U.S. FDA approval to initiate phase 1/2a clinical trials for SNK01, an NK cell therapy for Alzheimer’s disease in the U.S.Building on the results of the
The Ministry of Food and Drug Safety said it imposed an administrative penalty equivalent to a one-month suspension of clinical trials on Sanofi Pasteur Korea for the violation of labeling requirements in their ongoing meningococcal conjugate vaccine study.As a result of the violation of the Pharmac
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- A Korean company was honored with the title of "Best Poster" at the European Society for Medical Oncology Annual Meeting (ESMO 2023), the largest cancer society in Europe and one of the top three cancer societies in the world.Curoce
BARCELONA, Spain -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- CPHI Worldwide 2023 kicked off for a three-day run at the Fira Barcelona Gran Via convention center in Barcelona, Spain, on Tuesday.CPHI (Convention on Pharmaceutical Ingredients) is the world's largest pharma and bio exhi
JW Pharmaceutical, a Korean pharmaceutical company, said on Wednesday it signed a research agreement with Theraject Asia, a microneedle R&D company, to develop a microneedle-based hair loss treatment.Under the agreement, JW Pharmaceutical's Drug Research Center will utilize Theraject Asia's advanced
Iksuda Therapeutics (Iksuda), a U.K.-based developer of antibody-drug conjugates (ADCs), has successfully completed the first cycle of therapy with IKS014 in the first patient enrolled in a phase 1 study aimed at treating advanced HER2-positive solid tumors.This information was provided by the compa
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- The combination of Yuhan's Leclaza (lazertinib) and Janssen's Rybrevant (amivantamab) has been unveiled at the just-ended European Society for Medical Oncology (ESMO) 2023, Europe's largest cancer congress.On Monday, the results fro
Hanmi Pharm said the Ministry of Food and Drug Safety (MFDS) has approved its phase 3 clinical trial plan for efpeglenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to treat obesity.After submitting an investigational new drug (IND) application to the MFDS in July, Hanmi was able to secu
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- An enthusiastic standing ovation erupted in the Madrid Hall of the Ipema Convention Center, home to the European Society for Medical Oncology's Annual Meeting (ESMO 2023) in this Spanish capital city, on Wednesday.That occurred when
VaxCell-Bio, a Korean biotech company, said it has applied for product authorization with the Animal and Plant Quarantine Agency for Vaxleukin-15, which aims to become "the world's first immunotherapy exclusively for dogs."The company submitted the application after conducting clinical trials in 42
Janssen Korea, committed to innovation to stay ahead of diseases, pledged growth through cooperation with various stakeholders during a press conference celebrating its 40th anniversary on Monday.Established in 1983 as the Korean subsidiary of Johnson & Johnson's pharmaceutical division, Janssen Kor